Yamamoto Y et al. |
Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells. |
2008 |
Bioorg. Med. Chem. Lett. |
pmid:18556205
|
Cornelissen S et al. |
Whole-cell-based CYP153A6-catalyzed (S)-limonene hydroxylation efficiency depends on host background and profits from monoterpene uptake via AlkL. |
2013 |
Biotechnol. Bioeng. |
pmid:23239244
|
Kim D and Ortiz de Montellano PR |
Tricistronic overexpression of cytochrome P450cam, putidaredoxin, and putidaredoxin reductase provides a useful cell-based catalytic system. |
2009 |
Biotechnol. Lett. |
pmid:19458919
|
Jung HJ et al. |
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. |
2012 |
Blood |
pmid:22294726
|
Yuri T et al. |
Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. |
2004 |
Breast Cancer Res. Treat. |
pmid:15026623
|
Murren JR et al. |
Phase I study of perillyl alcohol in patients with refractory malignancies. |
2002 Mar-Apr |
Cancer Biol. Ther. |
pmid:12170772
|
Bailey HH et al. |
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. |
2004 |
Cancer Chemother. Pharmacol. |
pmid:15205914
|
Bailey HH et al. |
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:17885756
|
Azzoli CG et al. |
A phase I trial of perillyl alcohol in patients with advanced solid tumors. |
2003 |
Cancer Chemother. Pharmacol. |
pmid:12695855
|
Morgan-Meadows S et al. |
Phase I trial of perillyl alcohol administered four times daily continuously. |
2003 |
Cancer Chemother. Pharmacol. |
pmid:12904896
|